Indications of mycophenolate mofetil in liver transplantation

Transplantation

Volumn 80, Issue SUPPL. 1, 2005, Pages

  Klupp, Jochen ^a   Pfitzmann, Robert ^a   Langrehr, Jan M ^a   Neuhaus, Peter ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Immunosuppression; Liver transplantation; Mycophenolate mofetil

Indexed keywords

CALCINEURIN INHIBITOR; CELL ADHESION MOLECULE; CYCLOSPORIN; DACLIZUMAB; INOSINATE DEHYDROGENASE INHIBITOR; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; TACROLIMUS;

ACUTE GRAFT REJECTION; ALOPECIA; ANEMIA; B LYMPHOCYTE; BONE MARROW TOXICITY; CATARACT; CLINICAL TRIAL; CONFERENCE PAPER; DIABETES MELLITUS; DIARRHEA; DRUG ABSORPTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FIBROBLAST; GASTROINTESTINAL SYMPTOM; GINGIVA HYPERPLASIA; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPERTRICHOSIS; IMMUNOSUPPRESSIVE TREATMENT; LEUKOPENIA; LIVER TRANSPLANTATION; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; OBESITY; OSTEOPENIA; OSTEOPOROSIS; PRIORITY JOURNAL; PROPHYLAXIS; PURINE SYNTHESIS; SIDE EFFECT; SMOOTH MUSCLE FIBER; T LYMPHOCYTE; THROMBOCYTOPENIA;

ADRENAL CORTEX HORMONES; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; MYCOPHENOLIC ACID; TACROLIMUS;

EID: 27644458139     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000187133.53916.8f     Document Type: Conference Paper

References (65)

1. U.S. Multicenter FK506 Liver Study Group. A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation. N Engl J Med 1994; 331(17): 1110.
2. Neuhaus P, Klupp J, Langrehr JM, et al. Quadruple tacrolimus-based induction therapy including azathioprine and ALG does not significantly improve outcome after liver transplantation compared with a standard induction with tacrolimus and steroids: Results of prospective randomized trial. Transplantation 2000; 69 (11): 2343.
3. Morris RE, Hoyt EG, Eugui EM, Allison AC. Prolongation of rat heart allograft survival by RS-61443. Surg Forum 1989; 40: 337.
4. Hager PW, Collart FR, Huberman E, Mitchell BS. Recombinant human inosine monophosphate dehydrogenase type I and type II proteins. Purification and characterization of inhibitor binding. Biochem Pharmacol 1995; 49: 1323.
5. Allison AC, Eugui EM. Purine metabolism and immunosuppressive effects of mycophenolate mofetil (MMF). Clin Transpl 1996; 10 (1 Pt 2): 77.
6. Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 2000; 47 (2-3): 85.
7. Fraser-Smith EB, Rosete JD, Schatzman RC. Suppression by mycophenolate mofetil of the neointimal thickening caused by vascular injury in a rat arterial stenosis model. J Pharmacol Exp Ther 1995; 275 (3): 1204.
8. Gregory C, Huang X, Pratt R, et al. Treatment with rapamycin and mycophenolic acid reduces arterial intimal thickening produced by mechanical injury and allows endothelial replacement. Transplantation 1995; 59 (5): 655.
9. Allison AC, Eugui EM. Preferential suppression of lymphocyte proliferation by mycophenolic acid and predicted long-term effects of mycophenolate mofetil in transplantation. Transplant Proc 1994; 26 (6): 3205.
10. van Gelder T, Klupp J, Kavanau K, Morris RE. Novel mechanisms of action of mycophenolic acid (MPA): Inhibition of expression of CD28 and CD154 costimulatory molecules and induction of apoptosis in vivo in humans after treatment with mycophenolate mofetil (MMF). Transplantation 2000; 69 (8): S393.
11. European Mycophenolate Mofetil Cooperative Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet 1995; 345(8961): 1321.
12. Kobashigawa J, Miller L, Renlund D, et al. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate Mofetil Investigators. Transplantation 1998; 66 (4): 507.
13. Wiesner R, Rabkin J, Klintmalm G, et al. A randomized double-blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients. Liver Transpl 2001; 7 (5): 442.
14. Odorico J, Pirsch J, Knechtle S, et al. A study comparing mycophenolate mofetil to azathioprine in simultaneous pancreas-kidney transplantation. Transplantation 1998; 66 (12): 1751.
15. Klupp J, van Gelder, T, Dambrin C, et al. Sustained suppression of peripheral blood immune functions by treatment with mycophenolate mofetil correlates with reduced severity of cardiac allograft rejection. J Heart Lung Transplant 2004; 23 (3): 334.
16. Gregory CR, Huang X, Pratt RE, et al. Treatment with rapamycin and mycophenolic acid reduces arterial intimal thickening produced by mechanical injury and allows endothelial replacement. Transplantation 1995; 59 (5): 655.
17. Kobashigawa J. Further analysis of the intravascular ultrasound (IVUS) data from the randomized Mycophenolate Mofetil (MMF) trial in heart transplant recipients. 24th Annual Meeting of the International Society for Heart and Lung Transplantation (ISHLT). San Francisco, CA: April 21, 2004.
18. Pethig K, Heublein B, Wahlers T, et al. Mycophenolate mofetil for secondary prevention of cardiac allograft vasculopathy: influence on inflammation and progression of intimal hyperplasia. J Heart Lung Transplant 2004; 23(1): 61.
19. Klupp J, Bechstein WO, Platz KP, et al. Mycophenolate mofetil added to immunosuppression after liver transplantation-first results. Transpl Int 1997; 10 (3): 223.
20. Pfitzmann R, Klupp J, Langrehr JM, et al. Mycophenolate mofetil for immunosuppression after liver transplantation: a follow-up study of 191 patients. Transplantation 2003; 76 (1): 130.
21. Bullingham R, Monroe S, Nicholls A, Hale M. Pharmacokinetics and bioavailability of mycophenolate mofetil in healthy subjects after single-dose oral and intravenous administration. J Clin Pharmacol 1996; 36 (4): 315.
22. Bullingham RE, Nicholls A, Hale M. Pharmacokinetics of mycophenolate mofetil (RS61443): a short review. Transplant Proc 1996; 28 (2): 925.
23. Bullingham R, Shah J, Goldblum R, Schiff M. Effects of food and antacid on the pharmacokinetics of single doses of mycophenolate mofetil in rheumatoid arthritis patients. Brit J Clin Pharmacol 1996; 41 (6): 513.
24. Bullingham RE, Nicholls AJ, Kamm BR. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet 1998; 34 (6): 429.
25. Budde K, Glander P, Fritsche L, et al. Pharmacodynamic monitoring of mycophenolate mofetil by measurement of IMPDH acitivity [abstract]. Transplantation 2000; 69: S134.
26. Budde K, Glander P, Bauer S, et al. Pharmacodynamic monitoring of mycophenolate mofetil. Clin Chem Lab Med 2000; 38 (11): 1213.
27. Barten MJ, van Gelder, T, Gummert JF, et al. Pharmacodynamics (PD) of mycophenolate mofetil (MMF) after heart transplantation identify new mechanism of action and correlate with severity of rejection. Transplantation 1999; 67: S57.
28. Barten MJ, van Gelder, T, Gummert JF, et al. Pharmacodynamics of mycophenolate mofetil after heart transplantation: new mechanisms of action and correlations with histologic severity of graft rejection. Am J Transplant 2002; 2 (8): 719.
29. Klupp J, Holt DW, van Gelder, T. How pharmacokinetic and pharmacodynamic drug monitoring can improve outcome in solid organ transplant recipients. Transpl Immunol 2002; 9 (2-4): 211.
30. Klupp J, van Gelder, T, Dambrin C, et al. Mycophenolate mofetil pharmacodynamics and pharmacokinetics correlate with rejection score in a BN-to-LEW heterotopic heart transplant model. Transplant Proc 2001; 33 (3): 2170.
31. Eckhoff DE, McGuire BM, Frenette LR, et al. Tacrolimus (FK506) and mycophenolate mofetil combination therapy versus tacrolimus in adult liver transplantation. Transplantation 1998; 65 (2): 180.
32. Jain AB, Hamad I, Rakela J, et al. A prospective randomized trial of tacrolimus and prednisone versus tacrolimus, prednisone, and mycophenolate mofetil in primary adult liver transplant recipients: an interim report. Transplantation 1998; 66 (10): 1395.
33. Jain AB, Kashyap R, Kramer D, et al. Prospective randomized trial of tacrolimus and prednisone versus tacrolimus, prednisone, and mycophenolate mofetil: complete report on 350 primary adult liver transplantations. Transplant Proc 2001; 33 (1-2): 1342.
34. Lake JR, Chu AH, Steffen BJ, et al. Efficacy of triple therapy with Mycophenolate Mofetil (MMF), Tacrolimus (Tacro) and corticosteroids (CS) compared to Tacro and CS immunosuppression in liver transplantation: An analysis of the US liver transplant experience. Am J Transplant 2004: 266.
35. Fisher RA, Stone JJ, Wolfe LG, et al. Four-year follow-up of a prospective randomized trial of mycophenolate mofetil with cyclosporine microemulsion or tacrolimus following liver transplantation. Clin Transplant 2004; 18 (4): 463.
36. Herrero JI, Quiroga J, Sangro B, et al. Conversion of liver transplant recipients on cyclosporine with renal impairment to mycophenolate mofetil. Liver Transpl Surg 1999; 5 (5): 414.
37. Herrero JI, Quiroga J, Sangro B, et al. Conversion from calcineurin inhibitors to mycophenolate mofetil in liver transplant recipients with diabetes mellitus. Transplant Proc 2003; 35 (5): 1877.
38. Pfitzmann R, Klupp J, Langrehr JM, et al. Mycophenolate mofetil reduces calcineurin inhibitor-induced side effects after liver transplantation. Transplant Proc 2002; 34 (7): 2936.
39. Raimondo ML, Dagher L, Papatheodoridis GV, et al. Long-term mycophenolate mofetil monotherapy in combination with calcineurin inhibitors for chronic renal dysfunction after liver transplantation. Transplantation 2003; 75 (2): 186.
40. Schlitt HJ, Barkmann A, Boker KH, et al. Replacement of calcineurin inhibitors with mycophenolate mofetil in liver-transplant patients with renal dysfunction: a randomised controlled study. Lancet 2001; 357 (9256): 587.
41. Stewart SF, Hudson M, Talbot D, et al. Mycophenolate mofetil monotherapy in liver transplantation. Lancet 2001; 357 (9256): 609.
42. Koch RO, Graziadei IW, Schulz F, et al. Long-term efficacy and safety of mycophenolate mofetil in liver transplant recipients with calcineurin inhibitor-induced renal dysfunction. Transpl Int 2004; 17 (9): 518.
43. Planas JM, Martinez VC, Gonzalez ER, et al. Mycophenolate mofetil can be used as monotherapy late after liver transplantation. Am J Transplant 2004; 4 (10): 1650.
44. Ferraris JR, Duca P, Prigoshin N, et al. Mycophenolate mofetil and reduced doses of cyclosporine in pediatric liver transplantation with chronic renal dysfunction: changes in the immune responses. Pediatr Transplant 2004; 8 (5): 454.
45. Aw MM, Samaroo B, Baker AJ, et al. Calcineurin-inhibitor related nephrotoxicity- reversibility in paediatric liver transplant recipients. Transplantation 2001; 72 (4): 746.
46. Fairbanks KD, Thuluvath PJ. Mycophenolate mofetil monotherapy in liver transplant recipients: a single center experience. Liver Transpl 2004; 10(9): 1189.
47. Tur-Kaspa R, Laub O. Corticosteroids stimulate hepatitis B virus DNA, mRNA and protein production in a stable expression system. J Hepatol 1990; 11 (1): 34.
48. McCaughan G, Doughty A, Zekry A, Painter D. Immunopathogenesis of hepatitis B and hepatitis C infection in the nonimmunosuppressed and immunosuppressed state. Graft 1999; 2: 201.
49. Contreras JL, Eckhoff DE. Management of viral hepatitis after liver transplantation. Graft 1999; 2: 124.
50. Ringe B, Braun F, Schutz E, et al. A novel management strategy of steroid-free immunosuppression after liver transplantation: efficacy and safety of tacrolimus and mycophenolate mofetil. Transplantation 2001; 71 (4): 508.
51. Washburn K, Speeg KV, Esterl R, et al. Steroid elimination 24 hours after liver transplantation using daclizumab, tacrolimus, and mycophenolate mofetil. Transplantation 2001; 72 (10): 1675.
52. Neuhaus P, Blumhardt G, Bechstein WO, et al. Comparison of FK506- and cyclosporine-based immunosuppression in primary orthotopic liver transplantation. A single center experience. Transplantation 1995; 59(1): 31.
53. European FK506 Multicenter Liver Study Group. Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. Lancet 1994; 344 (8920): 423.
54. Hebert M, Ascher N, Lake J, et al. Mycophenolate Mofetil for prophylaxis against rejection following orthotopic liver transplantation. XVth World Congress of the Transplantation Society. Kyoto, Japan: August 28, 1994.
55. Hebert M, Ascher N, Lake J, et al. Four-year follow-up of mycophenolate mofetil for graft rescue in liver allograft recipients. Transplantation 1999; 67 (5): 707.
56. McDiarmid SV. Mycophenolate mofetil in liver transplantation. Clin Transplant 1996; 10 (1 Pt 2): 140.
57. Weppler D, Khan R, Fragulidis G, et al. Status of liver and gastrointestinal transplantation at the University of Miami. Clin Transpl 1996; 187.
58. Chardot C, Nicoluzzi JE, Janssen M, et al. Use of mycophenolate mofetil as rescue therapy after pediatric liver transplantation. Transplantation 2001; 71 (2): 224.
59. Platz KP, Mueller AR, Neuhaus R, et al. FK 506 and mycofenolate mofetil rescue for acute steroid-resistant and chronic rejection after liver transplantation. Transplant Proc 1997; 29 (7): 2872.
60. McDiarmid SV. Mycophenolate mofetil as induction therapy after liver transplantation. Liver Transpl Surg 1999;5 (4 Suppl 1): S85.
61. Tredger JM, Brown NW, Adams J, et al. Monitoring mycophenolate in liver transplant recipients: toward a therapeutic range. Liver Transpl 2004; 10 (4): 492.
62. Pescovitz MD, Conti M, Gonwa T, et al. Intravenous mycophenolate mofetil: safety, tolerability, and pharmacokinetics. Clin Transpl 2000; 14: 179.
63. Simmons WD, Rayhill SC, Sollinger HW. Preliminary risk-benefit assessment of mycophenolate mofetil in transplant rejection. Drug Safety 1997; 17 (2): 75.
64. Heemann U. Malignominzidenz unter der Therapie mit MMF. 6. Basler Transplantationsgespräch, vol 19 (2004). Basel, Schweiz, 31.10.-1.11.2003: Deutsche Medizinische Wochenschrift, 128. Jahrgang, 2003.
65. Cherikh WS, Kauffman HM, McBride MA, et al. Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation. Transplantation 2003; 76 (9): 1289.